Skip to content

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06555939
Enrollment
25
Registered
2024-08-15
Start date
2025-10-23
Completion date
2030-09-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

adolescents, young adults, resilience, sickle cell disease, collaborative care

Brief summary

Adolescents and young adults with sickle cell disease (SCD) face challenges managing their illness and maintaining their well-being. This study proposes to test the feasibility and acceptability of a resilience-promoting intervention through a Collaborative Care Model. The primary goal is to determine with the resilience intervention (PRISM) is feasible and acceptable for adolescents and young adults with SCD. Exploratory outcomes include whether this intervention improves depression, anxiety, and pain interference.

Detailed description

Adolescents and Young Adults (AYAs) with blood disorders are at risk for poor physical, psychological, and social outcomes. Sickle Cell Disease (SCD) is a life-limiting condition, defined as a group of inherited red blood cell disorders disproportionally affecting non-Hispanic Black, African American, and Hispanic/Latino groups. AYAs with SCD experience racial bias, disease-related stigma, and under-treated symptoms, all of which translate to additional challenges managing their illness and maintaining their well-being. This study proposes to address the gaps of mental health support for youth with SCD through delivery of a resilience-promoting intervention (PRISM) using a Collaborative Care Model (CoCM). The primary objective of this study is to test the feasibility and acceptability of a collaborative care model to sustainably deliver the PRISM intervention for AYAs with SCD. Leveraging successful strategies implemented for patients with cancer, we will pilot-test this approach with N=25 AYAs in the Dana-Farber Cancer Institute/Boston Children's hospital (DFCI/BCH) SCD clinic. The primary outcome of interest is feasibility, defined as \>50% enrollment. Secondary outcomes include patient reported outcomes of feasibility, acceptability, and satisfaction. Exploratory outcomes include assessment of depression, anxiety, and pain interference. We hypothesize this will be feasible and acceptable in this patient population.

Interventions

The interprofessional team will meet weekly to review survey scores, endorsed psychological and physical health needs, as well as other concerns. They will conduct assessments as a group that may include referrals for additional support.

PRISM targets 4 resilience resources: stress management, goal-setting, cognitive reframing and meaning-making. It is delivered one-on-one by trained coaches in English or Spanish via HIPAA compliant video-conference or in-person. Sessions are delivered every 1-2 weeks based on patient preference. To facilitate practice between sessions, all participants 13 or older have access to the digital PRISM app.

Sponsors

Boston Children's Hospital
Lead SponsorOTHER
National Institutes of Health (NIH)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* Aged ≥ 8 and ≤ 25 years of age at baseline * Diagnosed with Sickle Cell Disease (HbSS, HbSC, HbS-Beta Thalassemia, and other related hemoglobinopathies) * Receiving Medical Care at the DFCI/BCH Blood Disorders Center. * Scored \> 9 on Patient Health Questionnaire 9-item (PHQ-9) or Generalized Anxiety Disorder (GAD) * Able to speak English or Spanish language (for PRISM sessions) * Able to read English or Spanish language (for completion of surveys) * Cognitively able to participate in PRISM sessions and complete written questionnaires and surveys, as judged by the site investigator * Willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion criteria

\* does not meet above criteria

Design outcomes

Primary

MeasureTime frameDescription
Enrollment rate (feasibility)3-monthsfeasibility assessed by \>50% enrollment rate

Secondary

MeasureTime frameDescription
Acceptability3-months post-enrollmentprogram usefulness and willingness to recommend it (assessed via qualitative interviews)

Countries

United States

Contacts

CONTACTAbby Rosenberg, MD
abbyr_rosenberg@dfci.harvard.edu617.632.5286

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026